Epigenetics research is producing increasingly valuable inventions involving DNA methylation, histone modification, chromatin regulation, gene-expression control, epigenetic biomarkers, and therapeutic technologies. As these discoveries move from the laboratory into patent applications, one technical issue deserves particular attention: when and how biological sequence information must be presented in a sequence listing.
For patent applications containing qualifying nucleotide or amino acid sequences, the sequence listing is not simply an optional appendix. It is a standardized disclosure component designed to make sequence information searchable, interpretable, and accessible to patent offices and the public. WIPO Standard ST.26 now provides the international framework for sequence listings for applications filed on or after July 1, 2022.
For epigenetics inventions, careful preparation is especially important because an application may contain a mixture of genomic sequences, primers, probes, engineered nucleic acids, proteins, antibodies, guide sequences, and sequence-defined variants.
Why Sequence Listings Matter in Epigenetics
Epigenetics patent applications often involve sequence information even when the core invention concerns something other than the sequence itself.
For example, an invention may concern:
- A DNA methylation biomarker associated with a disease
- Primers for detecting methylation at a particular genomic locus
- Probes used in an epigenetic assay
- A modified nucleic acid molecule
- A gene-regulation construct
- A CRISPR-based epigenome-editing system
- A fusion protein used to modify chromatin
- An antibody or binding protein directed toward a modified epigenetic target
- A nucleic-acid-based therapeutic
- A panel of genomic markers
The patent specification may therefore contain dozens, hundreds, or even thousands of sequences.
Identifying which sequences require formal listing—and preparing them correctly—should be addressed early in the patent-drafting process.
When Is a Sequence Listing Required?
The answer depends on the applicable patent-office rules and the filing date.
Under WIPO ST.26, applications filed on or after July 1, 2022 that disclose nucleotide or amino acid sequences falling within the standard’s requirements must contain an ST.26-compliant sequence listing.
The USPTO similarly states that applications with a filing date on or after July 1, 2022 requiring sequence listings must use ST.26 XML, while applications filed before that date remain subject to ST.25. Importantly, the application filing date—not simply the date on which the sequence listing is submitted—determines which standard applies.
This distinction matters for continuations, national-phase applications, and other filings claiming priority to earlier applications.
The Priority Date Does Not Automatically Determine the Standard
A common misconception is that an earlier priority application containing an ST.25 listing allows every later application in the family to use ST.25.
That is not necessarily the case.
The USPTO specifically notes that an application filed on or after July 1, 2022 may require an ST.26 XML listing even when it claims benefit or priority to an earlier application containing an ST.25 listing. There is no general “grandfathering” of the old format into a later-filed application.
Patent teams handling large epigenetics portfolios should therefore determine the applicable sequence-listing standard separately for each filing.
What Epigenetic Sequences Should Be Reviewed?
A sequence audit should be performed alongside preparation of the patent specification.
Potential categories include:
Genomic sequences
If the application identifies particular genomic regions by sequence, those sequences should be reviewed against the applicable ST.26 requirements.
Primers
Diagnostic and research inventions frequently disclose forward and reverse primers. Each qualifying enumerated sequence may need an appropriate sequence identifier.
Probes
Probe sequences used to detect methylation or other epigenetic states should also be evaluated.
Guide RNAs and related sequences
Epigenome-editing inventions may disclose guide sequences or other nucleic-acid components. These should be reviewed carefully, particularly where multiple variants are disclosed.
Engineered proteins
Epigenetic editing systems can involve DNA-binding domains, catalytic domains, fusion proteins, antibodies, or other proteins. Qualifying amino acid sequences may need to appear in the listing.
Variants and fragments
A patent may disclose full-length sequences as well as fragments, substitutions, mutations, or engineered variants. Each sequence should be evaluated rather than assuming that a fragment can simply be treated as part of an existing sequence.
The USPTO notes, for example, that under ST.26 a separately enumerated subsequence meeting the applicable requirements is assigned its own SEQ ID number rather than merely being described as residues of another sequence.
Sequence Listing vs. Sequence Disclosure in the Specification
A sequence listing does not replace the substantive disclosure of the invention.
The specification still needs to explain the invention adequately, including the significance of particular sequences, how they are used, relevant embodiments, and relationships among sequences.
The sequence listing provides standardized sequence data that accompanies that disclosure.
For an epigenetics application, the specification might explain that a particular primer pair detects methylation at a biomarker locus, while the sequence listing provides the actual nucleotide sequences associated with the relevant SEQ ID numbers.
This division helps make the application both technically understandable and machine-searchable.
Preparing an ST.26 Sequence Listing
ST.26 requires the sequence listing to be presented as a single XML file. It contains a general information section and a sequence-data section. The sequence data includes the sequences and associated feature information.
WIPO provides WIPO Sequence, a dedicated software tool for creating and validating ST.26-compliant sequence listings. The USPTO also strongly recommends its use, although applicants are not legally required to use that particular software if another method produces a compliant ST.26 XML file.
A typical workflow involves:
- Identifying all potentially qualifying sequences.
- Assigning sequence identifiers.
- Entering the relevant sequence information.
- Adding required features and qualifiers.
- Checking consistency with the specification.
- Validating the ST.26 file.
- Reviewing the generated listing before filing.
- Filing the XML in the manner required by the relevant patent office.
Why Early Preparation Is Better
Sequence listings should not be left until the final hours before filing.
Epigenetics applications can evolve rapidly during drafting. Researchers may add additional biomarkers, primer pairs, variants, constructs, or experimental sequences during the patent-preparation process.
If the sequence listing is prepared too early and then not reconciled with the final specification, discrepancies can arise. Conversely, preparing it at the last minute can make it difficult to identify missing sequences or correct formatting problems.
A better approach is to create a sequence inventory early, update it during drafting, and perform a final reconciliation before filing.
Avoiding New Matter Problems
One of the most important reasons to prepare sequence information carefully before filing is the relationship between the sequence listing and the application’s disclosure.
A later-filed sequence listing should not be used as a vehicle for introducing substantive biological sequence information that was absent from the application as filed.
WIPO’s guidance explains that where a sequence listing is furnished later for purposes such as international search, it must not go beyond the disclosure of the international application as filed and must be accompanied by an appropriate statement.
For epigenetics inventions, this is particularly important because even a seemingly small sequence difference—such as a nucleotide substitution, deletion, or added sequence—can have substantive technical significance.
Patent counsel and inventors should therefore establish which sequences were actually disclosed and supported at the relevant filing date.
Consistency Between the Specification and Sequence Listing
One of the most useful quality-control steps is a cross-check between the specification, claims, drawings, tables, and sequence listing.
For example, if the specification refers to SEQ ID NO: 15 as a particular primer, the sequence associated with that identifier must be the same throughout the application.
The review should look for:
- Missing sequences
- Duplicate sequence identifiers
- Incorrect identifiers in the specification
- Typographical differences
- Incorrect sequence orientation
- Incorrect feature annotations
- Sequences appearing in claims but not in the listing
- Sequences in the listing that are not properly supported by the application
ST.26 itself does not prohibit the same sequence from appearing more than once with different identifiers, but the USPTO cautions that unnecessary duplication can create confusion.
Special Considerations for Diagnostic Epigenetics Patents
Epigenetic diagnostic inventions frequently use panels containing numerous biomarkers.
For example, an application could disclose a panel of methylation markers together with:
- Primer sequences
- Probe sequences
- Reference sequences
- Control sequences
- Amplification sequences
- Detection sequences
The patent team should determine which sequences meet the applicable listing requirements rather than assuming that every sequence appearing in an experimental example can be handled identically.
It is also useful to maintain a structured internal sequence database during drafting. This reduces the risk of copying errors and makes it easier to update related applications and continuation filings.
PCT Applications and Sequence Listings
For applicants pursuing international protection, sequence-listing requirements are particularly important.
WIPO states that, beginning July 1, 2022, PCT applications requiring sequence listings use ST.26, and ePCT supports XML sequence-listing uploads.
A sequence listing separately furnished to the International Searching Authority under PCT Rule 13ter may be used for search purposes without necessarily becoming part of the international application itself. WIPO’s current PCT guidance explains that such a listing is used for international search and may later be addressed during national-phase or amendment procedures.
For this reason, applicants should aim to prepare a compliant listing as part of the original filing package whenever required, rather than treating it as an afterthought.
A Practical Review Strategy
For universities, biotechnology companies, and research institutions, a repeatable sequence-listing workflow can significantly reduce errors.
Before filing an epigenetics patent application, the team should ask:
- Does the application disclose nucleotide or amino acid sequences?
- Which disclosed sequences fall within the applicable standard?
- What filing date determines whether ST.25 or ST.26 applies?
- Have all qualifying sequences been assigned the appropriate identifiers?
- Does every SEQ ID correspond to the correct sequence?
- Are the sequences accurately represented in the specification?
- Are variants and subsequences handled correctly?
- Has the XML been validated?
- Has the final listing been reconciled with the claims and description?
- Does the sequence listing contain only information properly supported by the application?
These checks are especially valuable for applications involving large sequence sets.
Conclusion
Sequence listings are a critical technical component of many modern epigenetics patent applications. As inventions increasingly combine genomic biomarkers, diagnostic assays, epigenome-editing systems, nucleic acids, and engineered proteins, careful management of sequence information can be just as important as careful drafting of the claims.
For applications filed on or after July 1, 2022, WIPO ST.26 provides the applicable international framework for qualifying sequence disclosures, using XML rather than the older ST.25 format
The best practice is to treat sequence-listing preparation as an integral part of patent drafting from the beginning. By identifying sequences early, maintaining consistent identifiers, validating the ST.26 XML, and ensuring that the listing matches the application as filed, patent applicants can reduce avoidable filing problems and create a stronger foundation for prosecution and international patent protection.